With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...
Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...
Vertex Pharmaceuticals (VRTX) announced updated data for povetacicept in IgA nephropathy and primary membranous nephropathy from the ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback